Changes in Ki-67 labeling indices during neoadjuvant chemotherapy for advanced ovarian cancer are associated with survival

International Journal of Gynecological Cancer

Volumn 20, Issue 4, 2010, Pages 555-560

  Pölcher, Martin ^a   Friedrichs, Nicolaus ^b,d   Rudlowski, Christian ^a   Fimmers, Rolf ^c   Keyver Paik, Mignon Denise ^a   Kübler, Kirsten ^a   Sauerwald, Axel ^a   Büttner, Reinhard ^b   Kuhn, Walther ^a   Braun, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

^b University of Cologne   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Ki 67; Neoadjuvant chemotherapy; Ovarian cancer; Prognostic factors

Indexed keywords

CARBOPLATIN; DOCETAXEL; KI 67 ANTIGEN; PARAFFIN;

ADULT; ADVANCED CANCER; AGED; ANTIBODY LABELING; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, PAPILLARY; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II AS TOPIC; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 77952277801     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181c104c0     Document Type: Article

References (18)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-2529.
3. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95: S161-S192.
4. Kuhn W, Rutke S, Spathe K, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer. 2001;92:2585-2591.
5. Vergote IB, Tropé CG, Amant F, et al. EORTC-GCG/NCIC-CTG Randomised Trial Comparing Primary Debulking Surgery With Neoadjuvant Chemotherapy in Stage IIIC-IV Ovarian, Fallopian Tube and Peritoneal Cancer (OVCA). Paper presented at 12th Biennial Meeting, International Gynecological Cancer Society (IGCS), 2008, Bangkok.
6. Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003;21:241-250.
7. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol. 2004;57:675-681.
8. Anttila M, Kosma VM, Ji H, et al. Clinical significance of alpha-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer. J Clin Oncol. 1998;16:2591-2600.
9. Blegen H, Einhorn N, Sjovall K, et al. Prognostic significance of cell cycle proteins and genomic instability in borderline, early and advanced stage ovarian carcinomas. Int J Gynecol Cancer. 2000;10:477-487.
10. Munstedt K, von Georgi R, Franke FE. Correlation between MIB1-determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas. Cancer Invest. 2004;22:185-194.
11. Goff BA, Ries JA, Els LP, et al. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure. Gynecol Oncol. 1998;70:378-385.
12. Pölcher M, Mahner S, Ortmann O, et al. Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancerVa prospective multicenter phase 2 trial (PRIMOVAR). Oncol Rep. 2009;22:605-613.
13. Garzetti GG, Ciavattini A, Goteri G, et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol. 1995;56:169-174.
14. Kritpracha K, Hanprasertpong J, Chandeying V, et al. Survival analysis in advanced epithelial ovarian carcinoma in relation to proliferative index of MIB-1 immunostaining. J Obstet Gynaecol Res. 2005;31:268-276.
15. Miller K, Price JH, Dobbs SP, et al. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma. J Clin Pathol. 2008;61:652-657.
16. Sassen S, Schmalfeldt B, Avril N, et al. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol. 2007;38:926-934.
17. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167-170.
18. Hall MD, Okabe M, Shen DW, et al. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495-535.